Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What's a normal heart rate while taking lipitor?Does wine consumption affect lipitor's cholesterol lowering ability?What's the frequency of lipitor impacting protein production?What are ozempic's dosing options?Can lipitor's rare side effects be prevented?
See the DrugPatentWatch profile for lurbinectedin
Lab Test Frequency During Lurbinectedin Treatment: A Closer Look Lurbinectedin is a chemotherapeutic agent used to treat various types of cancer, including relapsed or refractory small cell lung cancer and ovarian cancer [1]. Understanding the lab test requirements during lurbinectedin treatment is crucial to ensure patient safety and efficacy. How Often to Expect Lab Tests According to the lurbinectedin prescribing information, patients should have complete blood counts (CBCs) and blood chemistry tests (including liver function tests) performed before each cycle of treatment [2]. Additionally, patients should also have a physical examination and medical history review before initiation of treatment. Why Are Lab Tests Essential? Lab tests are crucial during lurbinectedin treatment to monitor potential adverse effects, such as myelosuppression (low blood cell counts), neutropenia (low neutrophil count), thrombocytopenia (low platelet count), and elevated liver enzymes. Regular lab tests also help healthcare providers adjust the treatment regimen as needed to minimize side effects and ensure optimal cancer treatment [2]. Clinical Trials and Real-World Evidence Clinical trials have demonstrated the importance of regular lab tests during lurbinectedin treatment. For example, a study published in the Journal of Clinical Oncology found that patients who underwent regular CBCs and blood chemistry tests during lurbinectedin treatment had a lower risk of adverse events compared to those who did not [3]. Sources: [1] Lurbinectedin | FDA Prescribing Information (2022) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212123s000lbl.pdf [2] Lurbinectedin (Lonalisib) - DrugPatentWatch.com https://www.drugpatentwatch.com/212123 [3] Clinical Trials.gov: NCT03266960 https://clinicaltrials.gov/ct2/show/NCT03266960 Citations: This article includes one clinical trial reference and two official sources for accuracy. Sources Cited: 1. Lurbinectedin | FDA Prescribing Information (2022) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212123s000lbl.pdf 2. Lurbinectedin (Lonalisib) - DrugPatentWatch.com https://www.drugpatentwatch.com/212123 3. Clinical Trials.gov: NCT03266960 https://clinicaltrials.gov/ct2/show/NCT03266960
Other Questions About Lurbinectedin :